LV-DC vaccine / SZGIMI - LARVOL DELTA

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine (clinicaltrials.gov) - P1/2 | N=100 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2030 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2029 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2024 ➔ Dec 2030 | Trial primary completion date: Jul 2023 ➔ Dec 2029

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. (PubMed, Int J Environ Res Public Health) - "COVID-19 vaccines obtained from classical and next-generation vaccine production platforms have entered clinicals trials. Biotechnology strategies of the first generation (attenuated and inactivated virus-CoronaVac, CoVaxin; BBIBP-CorV), second generation (replicating-incompetent vector vaccines-ChAdOx-1; Ad5-nCoV; Sputnik V; JNJ-78436735 vaccine-replicating-competent vector, protein subunits, virus-like particles-NVX-CoV2373 vaccine), and third generation (nucleic-acid vaccines-INO-4800 (DNA); mRNA-1273 and BNT 162b (RNA vaccines) have been used. Additionally, dendritic cells (LV-SMENP-DC) and artificial antigen-presenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The COVID-19 puzzle: a global nightmare. (PubMed, Environ Dev Sustain) - "mRNA-1273, ChAdOx1, Ad5-nCoV, INO-4800, LV-SMENP-DC and pathogen-specific aAPC are the most advanced and potential drug candidates against COVID-19. Recent studies have revealed any attractive vaccine candidates as promising therapeutic agents based on different strategies of vaccines. Here, the rationale of this review was also to provide an overview of the pathogenesis of the virus and summarize the updated potential vaccine candidates against SARS-CoV-2."

Clinical • Journal • Review • Infectious Disease • Novel Coronavirus Disease • Otorhinolaryngology • Pain • Pneumonia • Respiratory Diseases